KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Operating Leases: 2018-2024

Historic Operating Leases for Amneal Pharmaceuticals (AMRX) over the last 7 years, with Dec 2024 value amounting to $24.8 million.

  • Amneal Pharmaceuticals' Operating Leases rose 0.74% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.4 million, marking a year-over-year increase of 0.74%. This contributed to the annual value of $24.8 million for FY2024, which is 49.27% down from last year.
  • As of FY2024, Amneal Pharmaceuticals' Operating Leases stood at $24.8 million, which was down 49.27% from $48.9 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Operating Leases ranged from a high of $64.0 million in FY2021 and a low of $24.8 million during FY2024.
  • Over the past 3 years, Amneal Pharmaceuticals' median Operating Leases value was $48.9 million (recorded in 2023), while the average stood at $44.3 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Operating Leases rose by 2.36% in 2021, and later tumbled by 49.27% in 2024.
  • Over the past 5 years, Amneal Pharmaceuticals' Operating Leases (Yearly) stood at $62.5 million in 2020, then rose by 2.36% to $64.0 million in 2021, then decreased by 7.45% to $59.2 million in 2022, then dropped by 17.42% to $48.9 million in 2023, then plummeted by 49.27% to $24.8 million in 2024.